“a favorable trend”

A favorable trend was also observed for ORR (52.5% vs. 35.1%, p = 0.12) and OS (20.0 vs. 8.8 months; HR: 0.62; 95% CI: 0.35–1.10; p = 0.10) ( Figure 3 B).

There were no associations of VF with any ADRB2 variant, whereas the ADRA2C 322–325 Ins/Del genotype had a favorable OR (0.39 [0.22, 0.72], P =0.002) and Del carriers exhibited a favorable trend (OR 0.69, P =0.13).

Subclassifying AEs according to enteral stent patency, no significant difference was observed in terms of stent dysfunction rate (stent migration, stent obstruction, and relapse of GOO symptoms) between the two groups although a favorable trend was observed for EUS-GE (0% vs. 11.5 %, p = 0.16).

The proportion of patients surviving at the 12-month mark exhibited a favorable trend in the study group compared to the control (91.1% vs 87.6%), though statistical significance was not attained (p=0.202).

In contrast, the KEYNOTE-122 trial, which investigated pembrolizumab asmonotherapy in patients with recurrent or metastatic NPC who had previously failed platinum-based chemotherapy, did not report a significant improvement in OS in the pembrolizumab arm, despite showing a favorable trend (HR 0.9, 95% CI: 0.67–1.19, p = 0.2262).

Bcl-2 status was significant in ER-negative patients ( p = 0.010) and showed a favorable trend in ER-positive patients ( p = 0.259) (Fig. 3 ).

Comparing to treating only part of metastatic lesions, total irradiation of metastatic lesions was associated with superior PFS (HR, 0.44; 95 % CI, 0.18–1.11; p = 0.083), and higher radiation doses (BED 10 ≥ 60 Gy) showed a favorable trend to improve the PFS (HR, 0.71; 95 % CI, 0.36–1.39; p = 0.319).

The interim OS data did not suggest a favorable trend for osimertinib over placebo (36‐month OS rate, 84% vs. 74%, HR = 0.81, P = 0.53), indicating that the long‐term efficacy of LAURA treatment remains unclear.

Although there was a favorable trend, the study failed its primary composite endpoint (HR: 0.90; 95% CI: 0.78, p = 1.02).

It should be noted that our results showed a favorable trend from 5 μM, a dose similar to that used in the abovementioned studies [ 11 , 12 ]; however, 10 μM was used for subsequent experiments to achieve clear statistical significance.

The meta-analysis by Alrabiah (2019) evaluated implants inserted only in posterior areas and did not show a significant overall difference in survival rates between narrow-diameter implants (NDIs) and regular-diameter implants (RDIs), however it demonstrated a favorable trend towards narrow-diameter dental implants [ 41 ].

In women, rates in Argentina and Chile, starting from the highest ASRs in 1970–74 showed a favorable trend over the whole period.

It has been shown that there is a favorable trend in overall survival with platinum-based therapies in patients with HRR.

The lack of significant improvement in mortality rates due to falls in the Polish elderly population observed since 2009, despite a favorable trend in the first decade of the analysis, may be related to an increase in the dynamics of growth in the trend of the oldest people (i.e., those aged over 80), particularly noticeable in the last decade (from 6.4% to 8.5%).

After BR-PVS, four patients achieved postural control normalization measured by posturography, and one patient exhibited a favorable trend of improvement.

Only one small RCT in colorectal cancer collected data on the 3-year recurrence rate and revealed a favorable trend toward reduced cancer recurrence in patients receiving β-blockers[ 44 ].

Although there was no statistically significant difference in OS between the two groups (P=0.221), the subgroup analysis showed that patients in group A (mOS: 10.4, 95% CI: 0.3 to 20.6 months) exhibited a favorable trend in OS compared with group B (mOS: 18.0, 95% CI: 5.4 to 30.6 months) ( Figure 5B ).

NOACs have undoubtedly played a big role in preventing AF-related strokes and contributing to a favorable trend.

Moreover, a favorable trend in survival was observed in all patient regardless of molecular subtype (dMMR/MSI-H and pMMR/MSS).

The results of the pilot study provided information on the feasibility of using virtual reality equipment in this group of patients and showed a favorable trend of changes in the working memory in individual patients.

A favorable trend (–0.16% per month) was observed but not statistically significant due to the low number of patients.

The trial enrolled 804 patients, and on final analysis for primary end point (efficacy boundary survival), the results showed a favorable trend, but no statistically significant benefit for pembrolizumab arm HR 0.83 (05% CI, 0.68–1.03).

The GeparNUEVO trial used durvalumab in the neoadjuvant setting for TNBC and observed an increase in pCR, improvement in iDFS and DDFS, and a favorable trend in OS [ 210 , 211 ].

In PRO-STIP, no differences in persistence were reported between the subgroups analyzed (gender, age, obesity); only a favorable trend for having a better persistence was observed in previous treatment with 0 and 1 previous b/tsDMARDs (vs. ≥ 2 b/tsDMARDs).

92.5%; risk difference, -5.9% [95% CI: -15.8%-3.8%]); IRC-assessed PFS was similar with a favorable trend in zanubrutinib over orelabrutinib (HR, 0.74 [95% CI: 0.37-1.47]) and the 18-month PFS rate was numerically higher in zanubrutinib (82.9% vs. 78.7%).